Advantage Alpha Capital Partners LP lifted its position in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 27.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 293,865 shares of the company's stock after acquiring an additional 63,041 shares during the quarter. Stevanato Group accounts for 1.5% of Advantage Alpha Capital Partners LP's portfolio, making the stock its 20th largest position. Advantage Alpha Capital Partners LP owned about 0.10% of Stevanato Group worth $6,403,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. LPL Financial LLC lifted its stake in Stevanato Group by 24.6% in the fourth quarter. LPL Financial LLC now owns 85,721 shares of the company's stock worth $1,940,000 after purchasing an additional 16,915 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in Stevanato Group during the 4th quarter valued at $317,000. Teacher Retirement System of Texas grew its position in Stevanato Group by 56.3% in the 4th quarter. Teacher Retirement System of Texas now owns 1,250,000 shares of the company's stock valued at $27,238,000 after acquiring an additional 450,000 shares during the last quarter. William Blair Investment Management LLC purchased a new stake in Stevanato Group in the fourth quarter worth $1,026,000. Finally, Royce & Associates LP lifted its position in shares of Stevanato Group by 33.6% during the fourth quarter. Royce & Associates LP now owns 458,335 shares of the company's stock worth $9,987,000 after purchasing an additional 115,176 shares during the last quarter.
Stevanato Group Stock Up 3.9 %
Shares of Stevanato Group stock opened at €22.52 ($24.48) on Monday. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The company has a market cap of $6.82 billion, a P/E ratio of 47.91, a PEG ratio of 7.18 and a beta of 0.60. The firm's 50 day moving average price is €21.03 and its 200-day moving average price is €20.59. Stevanato Group S.p.A. has a 52-week low of €16.56 ($18.00) and a 52-week high of €33.49 ($36.40).
Stevanato Group (NYSE:STVN - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. On average, sell-side analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts recently commented on STVN shares. UBS Group reduced their price target on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a research note on Friday, March 7th. Bank of America lifted their price target on shares of Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, December 13th. William Blair reissued an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Wolfe Research assumed coverage on Stevanato Group in a research report on Friday, December 13th. They set an "outperform" rating and a $28.00 target price for the company. Finally, Morgan Stanley restated an "equal weight" rating and set a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of €27.75 ($30.16).
Get Our Latest Report on STVN
Stevanato Group Company Profile
(
Free Report)
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stevanato Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.
While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
